R.E. Kast
This paper is a technical note showing how the established pharmacodynamic actions of four non-oncology drugs happen to inhibit several established pathophysiological mechanisms active in driving or facilitating breast cancers’ growth. The resulting four repurposed drug regimen, C2AZ, uses the analgesic drug celecoxib; the antifungal drug clotrimazole; a drug used to treat rheumatoid arthritis, auranofin; and a drug used to treat asthma, zileuton. All four have a large database showing that they inhibit one or more growth driving pathways of breast cancer. The four drugs of C2AZ have been well tolerated in general medical practice and no drug-drug interaction is predictable. All four are old, cheap, generic drugs. They are predicted to be growth retarding rather than directly cytotoxic so C2AZ would best be studied in an adjunctive role.This paper is a technical note showing how the established pharmacodynamic actions of four non-oncology drugs happen to inhibit several established pathophysiological mechanisms active in driving or facilitating breast cancers’ growth. The resulting four repurposed drug regimen, C2AZ, uses the analgesic drug celecoxib; the antifungal drug clotrimazole; a drug used to treat rheumatoid arthritis, auranofin; and a drug used to treat asthma, zileuton. All four have a large database showing that they inhibit one or more growth driving pathways of breast cancer. The four drugs of C2AZ have been well tolerated in general medical practice and no drug-drug interaction is predictable. All four are old, cheap, generic drugs. They are predicted to be growth retarding rather than directly cytotoxic so C2AZ would best be studied in an adjunctive role.
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi